These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8324147)

  • 1. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
    Hecht DW; Osmolski JR; O'Keefe JP
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
    Snydman DR; McDermott L; Cuchural GJ; Hecht DW; Iannini PB; Harrell LJ; Jenkins SG; O'Keefe JP; Pierson CL; Rihs JD; Yu VL; Finegold SM; Gorbach SL
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
    Borobio MV; Domínguez MC; Pallares JA; Perea EJ
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
    Fernández-Canigia L; Litterio M; Legaria MC; Castello L; Predari SC; Di Martino A; Rossetti A; Rollet R; Carloni G; Bianchini H; Cejas D; Radice M; Gutkind G;
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
    Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
    Bandoh K; Ueno K; Watanabe K; Kato N
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
    Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y
    Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.
    Karlowsky JA; Walkty AJ; Adam HJ; Baxter MR; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1247-52. PubMed ID: 22203594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992.
    Tanaka-Bandoh K; Kato N; Watanabe K; Ueno K
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S352-5. PubMed ID: 7548596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.